- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00007839
Beta Alethine in Treating Patients With Low-Grade Lymphoma
Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With B-Cell Lymphoma
RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing.
PURPOSE: Phase I/II trial to study the effectiveness of beta alethine in treating patients who have low-grade lymphoma.
Study Overview
Detailed Description
OBJECTIVES:
- Determine the antitumor effects of low-dose beta-alethine in patients with low grade B-cell lymphoma.
- Assess the effects of this regimen on delayed-type hypersensitivity in these patients.
- Assess the safety of this regimen in this patient population.
OUTLINE: This is an multicenter study.
Patients receive low-dose beta-alethine subcutaneously once every 2 weeks for a total of 6 doses in the absence of unacceptable toxicity. Patients with no evidence of tumor progression may receive additional courses of therapy.
Patients are followed for 2 weeks from the last dose or for a minimum of 30 days if they withdraw due to an adverse event.
PROJECTED ACCRUAL: Approximately 13-37 patients will be accrued for this study.
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Rockville, Maryland, United States, 20852
- Victory Over Cancer
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed low grade B-cell lymphoma
- Measurable residual disease after maximal response to prior chemotherapy OR
- Indolent disease not yet requiring therapy
- No congenital immunodeficiency associated lymphoma
- No primary lymphoma of the brain
- No active brain involvement or leptomeningeal disease NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Karnofsky 50-100%
Life expectancy:
- At least 4 months
Hematopoietic:
- Neutrophil count at least 1,500/mm3
- Platelet count at least 100,000/mm3
- Hemoglobin at least 10 g/dL
Hepatic:
- Bilirubin less than 2.0 mg/dL
- SGOT/SGPT no greater than 2.5 times upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present)
Renal:
- Creatinine no greater than 2.0 mg/dL
- Calculated creatinine clearance at least 60 mL/min
Cardiovascular:
- No uncontrolled angina, heart failure, or arrhythmia
- No acute changes on EKG
Other:
- Not pregnant or nursing
- Fertile patients must use effective contraception
- HIV negative
- No AIDS
- Adequate nutritional status (total protein at least 60.0 g/L)
- No active bacterial infections (e.g., abscess or with fistula)
- No nonmalignant disease that would preclude study
- No history of alcoholism, drug addiction, or psychotic disorders that would preclude study
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Prior bone marrow transplantation allowed
- At least 4 weeks since prior immunotherapy or cytokines
Chemotherapy:
- See Disease Characteristics
- Prior intensive chemotherapy with stem cell support allowed
- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or high dose carboplatin)
Endocrine therapy:
- No concurrent corticosteroids
Radiotherapy:
- At least 4 weeks since prior radiotherapy to more than 25% of bone marrow
Surgery:
- Recovered from prior surgery
- No prior solid organ transplantation
Other:
- No concurrent antiinflammatory agents including aspirin, or over the counter or prescription nonsteroidal antiinflammatory drugs
- No concurrent immunosuppressive agents
- No other concurrent investigational agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- recurrent adult diffuse small cleaved cell lymphoma
- stage III grade 1 follicular lymphoma
- stage III grade 2 follicular lymphoma
- stage III adult diffuse small cleaved cell lymphoma
- stage IV grade 1 follicular lymphoma
- stage IV grade 2 follicular lymphoma
- stage IV adult diffuse small cleaved cell lymphoma
- stage I grade 1 follicular lymphoma
- stage I grade 2 follicular lymphoma
- stage I adult diffuse small cleaved cell lymphoma
- recurrent grade 1 follicular lymphoma
- recurrent grade 2 follicular lymphoma
- contiguous stage II grade 1 follicular lymphoma
- contiguous stage II grade 2 follicular lymphoma
- contiguous stage II adult diffuse small cleaved cell lymphoma
- noncontiguous stage II grade 1 follicular lymphoma
- noncontiguous stage II grade 2 follicular lymphoma
- noncontiguous stage II adult diffuse small cleaved cell lymphoma
- noncontiguous stage II small lymphocytic lymphoma
- noncontiguous stage II marginal zone lymphoma
- recurrent marginal zone lymphoma
- recurrent small lymphocytic lymphoma
- stage I marginal zone lymphoma
- stage I small lymphocytic lymphoma
- stage III small lymphocytic lymphoma
- stage III marginal zone lymphoma
- stage IV small lymphocytic lymphoma
- stage IV marginal zone lymphoma
- contiguous stage II marginal zone lymphoma
- contiguous stage II small lymphocytic lymphoma
- extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
- nodal marginal zone B-cell lymphoma
- splenic marginal zone lymphoma
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000068279
- LIFETIME-LTP-99-02
- LIFETIME-IRB-0300202
- NCI-V00-1628
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
University of WashingtonAstraZenecaRecruitingB-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Follicular Lymphoma to Diffuse...United States
-
Iksuda Therapeutics Ltd.RecruitingFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin LymphomaAustralia, Canada, United States
-
Epizyme, Inc.CompletedFollicular Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumors | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal LymphomaUnited Kingdom
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Massachusetts General HospitalVarian Medical SystemsNot yet recruitingLymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell LymphomaUnited States
-
Juno Therapeutics, a Subsidiary of CelgeneActive, not recruitingFollicular Lymphoma | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma | Mantle-cell LymphomaUnited States
Clinical Trials on beta alethine
-
LifeTime PharmaceuticalsUnknown
-
LifeTime PharmaceuticalsUnknownMultiple Myeloma and Plasma Cell Neoplasm | Precancerous ConditionUnited States
-
Oslo Metropolitan UniversityUniversity of Oslo; Nofima; Mills DACompletedGut Microbiota | Satiety | Post Prandial Blood GlucoseNorway
-
Profil Institut für Stoffwechselforschung GmbHIcahn School of Medicine at Mount Sinai; Heart and Diabetes Center North-Rhine...CompletedType 2 Diabetes MellitusGermany
-
ISU Abxis Co., Ltd.RecruitingFabry DiseaseKorea, Republic of
-
Metabolic Technologies Inc.Koach Sport and NutritionCompletedSurvival TrainingIsrael
-
AZ-VUBUniversitaire Ziekenhuizen KU Leuven; Universitair Ziekenhuis BrusselUnknown
-
Lund UniversityCompleted
-
Maastricht University Medical CenterCompleted
-
Instituto de Ciencia y Tecnología de Alimentos...Ministerio de Economía y Competitividad, SpainCompletedInsulin Resistance | Overweight/ObesitySpain